Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gabriella L. Mariani"'
Autor:
Susan M. Domchek, Tiziana Usari, Gabriella L. Mariani, Jens Rüter, Jennifer A. Trosko, Prudence Dorazio, Denis Soulieres, Divis Khaira, Elaina M. Gartner, Magi Khalil, Patricia M. LoRusso, Robert H. Vonderheide
Purpose: Tremelimumab is a fully human monoclonal antibody specific for CTL-associated antigen 4 (CTLA4) with single-agent activity in certain tumors but has not been evaluated in patients with breast cancer.Experimental Design: In a phase 1 study, 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e8fc5dcbea0fdaffb4d23736443ee07
https://doi.org/10.1158/1078-0432.c.6518074
https://doi.org/10.1158/1078-0432.c.6518074
Autor:
Susan M. Domchek, Tiziana Usari, Gabriella L. Mariani, Jens Rüter, Jennifer A. Trosko, Prudence Dorazio, Denis Soulieres, Divis Khaira, Elaina M. Gartner, Magi Khalil, Patricia M. LoRusso, Robert H. Vonderheide
Supplementary Data from Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c3e12c7e089d4965f17d20ed5ed33d8
https://doi.org/10.1158/1078-0432.22440799.v1
https://doi.org/10.1158/1078-0432.22440799.v1
Autor:
Jean-Pascal Machiels, Sylvie Rottey, Josef Hoefler, Juergen Braunger, Daniela Fischer, Marie Laruelle, Lore Lapeire, Daniela Boggiani, Sara Cresta, Mahmoud Ould-Kaci, Matteo Duca, Stefania Salvagni, Silvia Damian, Filippo de Braud, Alexandre Dermine, Marcello Tiseo, Juliane Rascher, Gabriella L Mariani
Publikováno v:
Cancers
Volume 12
Issue 6
CANCERS
Cancers, Vol. 12, no. 6, p. 1425 [1-12] (2020)
Cancers, Vol 12, Iss 1425, p 1425 (2020)
Volume 12
Issue 6
CANCERS
Cancers, Vol. 12, no. 6, p. 1425 [1-12] (2020)
Cancers, Vol 12, Iss 1425, p 1425 (2020)
This phase 1 trial (NCT01938846) determined the maximum tolerated dose (MTD) of the mTOR serine/threonine kinase inhibitor, BI 860585, as monotherapy and with exemestane or paclitaxel in patients with advanced solid tumors. This 3+3 dose-escalation s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc12380ff2c080e3ad867101567bdd9c
https://pubmed.ncbi.nlm.nih.gov/32486385
https://pubmed.ncbi.nlm.nih.gov/32486385
Autor:
Gabriella L Mariani, Thomas W. Grunt
Publikováno v:
Current Cancer Drug Targets. 13:188-204
Breast cancer is one of the most prevalent and devastating malignant diseases in women worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is declining. This is mainly due to early diagnosis and potent therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c323f0da0b5149a5d5ff3e4b5f76852a
https://doi.org/10.2174/1568009611313020008
https://doi.org/10.2174/1568009611313020008
Autor:
Jens Rüter, Divis Khaira, Jennifer A. Trosko, Gabriella L. Mariani, Denis Soulières, Susan M. Domchek, Prudence Dorazio, Tiziana Usari, Magi Khalil, Patricia LoRusso, Elaina M. Gartner, Robert H. Vonderheide
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 16(13)
Purpose: Tremelimumab is a fully human monoclonal antibody specific for CTL-associated antigen 4 (CTLA4) with single-agent activity in certain tumors but has not been evaluated in patients with breast cancer. Experimental Design: In a phase 1 study,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d97d1c15afaaef6bf47804f46d95133f
https://pubmed.ncbi.nlm.nih.gov/20479064
https://pubmed.ncbi.nlm.nih.gov/20479064